A peek behind the paper: suppressing the FGF19/FGFR4 axis in cancer
In this interview, corresponding author Yong Teng (Augusta University; GA, USA) discusses how targeting the FGF19/FGFR4 axis could be used to develop therapies for specific FGF19-driven tumors, as well as increase sensitivity to radiotherapy and chemotherapy.
Please sign in or register for FREE
Sign in to RxNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Future Medicinal Chemistry FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RxNet account also gives you access to communities on regenerative medicine, real-world evidence and 3D printing in medicine. Find out more>>